A multicenter, open-label, randomized controlled trial to evaluate the efficacy of
fluticasone propionate (metered dose inhaler - MDI) added to standard care at early stage of
COVID-19 in reducing the incidence of adverse outcomes (any of those following: oxygen
therapy, systemic corticosteroids, hospitalization, mechanical ventilation, and mortality) in
symptomatic patients either from 18 to 49 years of age with risk factors or older than 50
years.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Medicine and Pharmacy at Ho Chi Minh City